Decision was based on the results of a pre-planned review of study data
News
Researchers identify molecular ‘cookie cutter’ technique for COVID-19 drug discovery
Researchers are aiming to isolate a stable form of the COVID-19 encounter complex
Daiichi Sankyo inks digital partnership for atrial fibrillation
Collaborative agreement will focus on improving detection and diagnosis of AF
AstraZeneca’s COVID-19 vaccine shows 79% efficacy in US trial
Jab was also found to have 100% efficacy at preventing severe disease and hospitalisation
FDA nod for Kiniksa’s Arcalyst in recurrent pericarditis
Recurrent pericarditis is an autoinflammatory cardiovascular disease
‘Formal review’ of GP access arrangements needed, says Healthwatch
UK-based charity conducted a review of GP access between April 2019 and December 2020
NICE recommends Kyprolis triple combination treatment for multiple myeloma
Kyprolis plus lenalidomide and dexamethasone approved as a second-line treatment
Roche’s Tecentriq improves disease-free survival in early lung cancer
Tecentriq is approved in five lung cancer indications currently
Havas Lynx and Syneos take home most agency Golds at PM Society awards
On the client side, AstraZeneca came out on top with four Golds, one Silver and one Bronze awards
EU authorisation for XPhyto’s rapid COVID-19 PCR test
PCR-based test has a sample collection to result time of 25 minutes
ICR’s ‘resistance-busting’ drug advances into Phase I trial
EP0042 is a dual-inhibitor drug designed to block the activity of two cancer-driving proteins
NICE approves Lynparza plus Avastin via Cancer Drugs Fund
Genomic HRD testing to be launched to support the introduction of this treatment regimen
UK and EU regulators reaffirm the safety of AZ/Oxford Uni’s COVID-19 vaccine
MHRA and EMA conclude the vaccine’s benefits continue to outweigh risks
GSK launches late-stage study of long-acting antibody for severe asthma
GSK’294 is designed to deliver long-acting suppression of IL-5 in severe eosinophilic asthma patients
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments
In the UK, over seven million people are affected by cardiovascular disease
